Addex director equity strikes reset to $0.032

Addex director Jason Raleigh Nunn reported neutral net changes as his shares and options were administratively repriced to a lower exercise price.

Rhea-AI Filing Summary

Addex Therapeutics Ltd. (ADXN) director Jason Raleigh Nunn reported compensation-related adjustments on September 2, 2026 with no net change in his positions. He returned and simultaneously re-received 219,561 shares of Common Stock and 50,000 stock options, reflecting the Remuneration Committee’s decision to reprice the related strike and exercise prices to $0.032 per share while leaving all other terms unchanged. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Nunn Jason Raleigh

Role Director

Type	Security	Shares	Price	Value
Disposition	Stock-option (Right to Buy) F3, F2	50,000	$0.00	$0.00
Grant/Award	Stock-option (Right to Buy) F3, F2	50,000	$0.00	$0.00
Disposition	Common Stock F1	219,561	$0.00	$0.00
Grant/Award	Common Stock F1	219,561	$0.00	$0.00

Holdings After Transaction: Stock-option (Right to Buy) — 50,000 contracts (Direct); Common Stock — 219,561 shares (Direct)

Footnotes (3)

1. F1. Represents 219,561 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 128,238 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 91,323 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable.The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026.
2. F2. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of options was repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable.
3. F3. The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026.

Key Figures

Common Shares adjusted: 219,561 shares Options adjusted: 50,000 options New strike/exercise price: $0.032 per share +4 more

7 metrics

Common Shares adjusted 219,561 shares Shares of Common Stock repriced under deferred strike price payment plan

Options adjusted 50,000 options Stock options repriced on September 2, 2026

New strike/exercise price $0.032 per share Repriced for options and related plan units on September 2, 2026

Prior option exercise price $0.062 per share Original exercise price for the 50,000 stock options before repricing

Original strike price tranche 1 $0.16 per share Initial strike price for 128,238 shares acquired October 26, 2022

Original strike price tranche 2 $0.053 per share Initial strike price for 91,323 shares acquired November 27, 2023

FX rate used $1.2296 per CHF 1.00 Conversion rate for reporting exercise prices in U.S. dollars as of September 2, 2026

Key Terms

deferred strike price payment plan, exercise price, Rule 16b-6(d), Rule 16b-3, +1 more

5 terms

deferred strike price payment plan financial

"acquired on October 26, 2022 under the deferred strike price payment plan"

exercise price financial

"the exercise price of options was repriced to $0.032"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Rule 16b-6(d) regulatory

"Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3"

Rule 16b-3 regulatory

"Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3"

Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.

exercise price is reported in U.S. dollars financial

"The exercise price is reported in U.S. dollars and reflects the conversion"

FAQ

What did ADXN director Jason Raleigh Nunn report on this Form 4?

He reported administrative adjustments on September 2, 2026, returning and re-receiving 219,561 Common Shares and 50,000 stock options in connection with a repricing of the related strike and exercise prices to $0.032 per share, with all other terms unchanged.

Were Jason Raleigh Nunn’s Addex (ADXN) share holdings increased or reduced?

The reported transactions show no net change in his share or option positions. Equal numbers of shares and options were disposed to and re-acquired from the issuer to reflect the new $0.032 pricing terms.

What happened to the exercise price of Jason Raleigh Nunn’s ADXN options?

On September 2, 2026, the Remuneration Committee’s decision was implemented and the exercise price of the options was repriced to $0.032 per share, with all other option terms remaining unchanged, according to the footnotes.

What are the 219,561 Addex (ADXN) shares referenced in the Form 4?

They represent 219,561 Common Shares listed on SIX Swiss Exchange that were previously acquired through option exercises under a deferred strike price payment plan; their strike prices were adjusted so all related units now carry a $0.032 strike price.

Was a Rule 10b5-1 trading plan involved in these ADXN transactions?

No. The Form 4 indicates no Rule 10b5-1 trading plan for these transactions, and the footnotes describe them as option and share repricings exempt under Rule 16b-6(d) and Rule 16b-3 of the Exchange Act.

How were the ADXN strike prices converted to U.S. dollars?

The footnotes state the strike and exercise prices are reported in U.S. dollars and reflect conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 04:07 PM Accepted by SEC EDGAR 09/04/2026 - 04:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nunn Jason Raleigh

(Last) (First) (Middle)

CHEMIN DES MINES 9

(Street)

GENEVA CH-1202

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
Addex Therapeutics Ltd. [ ADXN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol
[[ADXN]]

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2026		D(1)		219,561	D	$0(1)	0	D
Common Stock	09/02/2026		A(1)		219,561	A	$0(1)	219,561	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock-option (Right to Buy)	$0.062(3)	09/02/2026		D(2)			50,000	01/08/2024	01/07/2034	Common Stock	50,000	$0	0	D
Stock-option (Right to Buy)	$0.032(3)	09/02/2026		A(2)		50,000		01/08/2024	01/07/2034	Common Stock	50,000	$0	50,000	D

Explanation of Responses:

1. Represents 219,561 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 128,238 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 91,323 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable.The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026.

2. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of options was repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable.

3. The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026.

	/s/ Lenaic Nathanael Teyssedou by power of attorney	09/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)